A Phase 1/2 interventional study of MLN8237 (Alisertib) in Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer and Small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-15.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda — 1 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Takeda.
Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 1/2, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 273 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 101 across the 17 interventional studies, 94 across the 10 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735327TakedaA Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY | 2027-04-26 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
Following the determination of the Recommended Phase 2 Dose (RP2D) and schedule (Phase 1), 20 response-evaluable patients in each of the 5 tumor indications will be enrolled (Phase 2-Stage 1). An interim analysis will determine which tumor indications will proceed to enroll an additional 25 patients (Phase 2-Stage 2) to further evaluate Overall Response Rate (ORR) and other secondary endpoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MLN8237 administered as an enteric-coated tablet (ECT)
Drug: MLN8237 (Alisertib)
Phase 1: MLN8237 will be administered orally twice a day on a 7-day dosing schedule Phase 2: MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period.
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of the following considered related to alisertib by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/cubic meter \[cells/mm\^3\]) for \>7 days; Grade 4 neutropenia with coincident fever; Grade 4 thrombocytopenia (platelets \<25,000 cells/mm3) for \>7 days; Platelet count \<10,000 cells/mm3; Grade 3 thrombocytopenia with clinically significant bleeding; Delay in initiation of the subsequent therapy cycle by \>7 days due to treatment-related toxicity; \>=Grade 3 nonhematological toxicity except \>=Grade 3 nausea/emesis occurred in the absence of optimal antiemetic therapy; \>=Grade 3 diarrhea occurred in the absence of optimal supportive therapy with loperamide/comparable antidiarrheal; Grade 3 fatigue for \<1 week; Other Grade 3 nonhematological toxicity that could be safely, reliably controlled to \<=Grade 2 with appropriate treatment.
Time frame: Phase 1: Cycle 1 Day 1 to Cycle 2 Day 21
Phase 2: Percentage of Participants With Objective Response
Percentage of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeter \[mm\]). No new lesions. PR was defined as greater than or equal to (\>=) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline until complete response or partial response, assessed every 2 cycles up to end of study (up to 50 cycles)
Phase 2: Progression-free Survival (PFS)
PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.
Time frame: Baseline until progressive disease, assessed every 2 cycles up to end of study (up to 50 cycles)
Phase 2: Time to Disease Progression (TTP)
Time in days from start of study treatment to first documentation of objective tumor progression. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.
Time frame: Baseline until disease progression, assessed every 2 cycles up to end of study (up to 50 cycles)
Phase 2: Duration of Response (DOR)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response=(the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1). CR: complete disappearance of all target lesions and non-target disease, except nodal disease; all nodes decreased to normal; no new lesions. PR: \>=30% decrease under baseline of the sum of diameters of all target lesions; no unequivocal progression of non-target disease; no new lesions. Tumor progression: \>=20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study); absolute increase of \>=5 mm; appearance of \>=1 new lesions is also considered progression. DOR calculated for the subgroup of participants with objective response.
Time frame: Baseline up to Week 50
Phase 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events and Serious Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.
Time frame: Baseline up to 30 days after the last dose of study drug
Phase 1: Cmax- Maximum Observed Plasma Concentration for Alisertib
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours post-dose
Phase 1: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib
Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.
Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Phase 1: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib
Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.
Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Phase 1: Terminal Phase Elimination Half-life (T1/2) for Alisertib
Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
Time frame: Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Phase 1: Rac- Accumulation Ratio for Alisertib
Rac was estimated as a ratio of AUC (0-tau) at Day 7 and AUC (0-tau) at Day 1. Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.
Time frame: Days 1 and 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Phase 1: Peak to Trough Ratio for Alisertib
Peak to trough ratio was estimated as a ratio of Cmax at Day 7 and the minimum observed plasma concentration (Ctrough) of alisertib at Day 7. Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Ctrough is the minimum plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Phase 1: Steady State Oral Clearance (CLss/F) for Alisertib
CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-tau), expressed in liter per hour (L/hr).
Time frame: Day 7: predose, 30 minutes, 1, 2, 3, 4, 6, 8, and 12 hours postdose
Phase 2: Relationship Between Clinical Response and Molecular Markers of Response
In SCLC,chemo-sensitive/resistant population were analyzed;in breast cancers,ER2 and ER2 status were analyzed.HR+ =estrogen receptor-positive or progesterone receptor-positive. HER+ =human epidermal growth factor receptor 2 (HER2). Triple negative =negative for estrogen receptors, progesterone receptors, and HER2.Clinical response according to RECIST version 1.1. CR:complete disappearance of all target lesions,non-target disease,except nodal disease;all nodes decrease to normal (short axis \<10 mm);no new lesions. PR:\>=30% decrease under baseline of the sum of diameters of all target lesions (SLD);short axis was used in the sum for target nodes,longest diameter used in the sum for all other target lesions;no unequivocal progression of non-target disease;no new lesions. Progressive Disease (PD): \>=20% rise in SLD from the smallest value on study;unequivocal progression of existing non-target lesions. Stable Disease (SD):Neither sufficient shrinkage for PR nor sufficient increase for PD.
Time frame: 12 months
Participants took part in the study at 42 investigative sites in France, Poland, the Czech Republic, and the United States from 16 February 2010 to 25 April 2014.
| Milestone | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg | Phase 1: MLN8237 60 mg | Phase 1: MLN8237 50 mg- Pancreatic Cancer | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 3 | 4 | 12 | 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1 | 3 | 4 | 11 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg | Phase 1: MLN8237 60 mg | Phase 1: MLN8237 50 mg- Pancreatic Cancer | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 53 | 55 | 55 | 26 | 60 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 53 | 50 | 53 | 23 | 58 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 3 | 2 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 |
Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of the following considered related to alisertib by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/cubic meter \[cells/mm\^3\]) for \>7 days; Grade 4 neutropenia with coincident fever; Grade 4 thrombocytopenia (platelets \<25,000 cells/mm3) for \>7 days; Platelet count \<10,000 cells/mm3; Grade 3 thrombocytopenia with clinically significant bleeding; Delay in initiation of the subsequent therapy cycle by \>7 days due to treatment-related toxicity; \>=Grade 3 nonhematological toxicity except \>=Grade 3 nausea/emesis occurred in the absence of optimal antiemetic therapy; \>=Grade 3 diarrhea occurred in the absence of optimal supportive therapy with loperamide/comparable antidiarrheal; Grade 3 fatigue for \<1 week; Other Grade 3 nonhematological toxicity that could be safely, reliably controlled to \<=Grade 2 with appropriate treatment.
| participants | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg | Phase 1: MLN8237 60 mg | Phase 1: MLN8237 50 mg- Pancreatic Cancer |
|---|---|---|---|---|---|---|
| Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) | 0 | 0 | 0 | 2 | 0 | 0 |
Percentage of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeter \[mm\]). No new lesions. PR was defined as greater than or equal to (\>=) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|
| Phase 2: Percentage of Participants With Objective Response | 18 (9 to 32) | 9 (2 to 20) | 9 (2 to 21) | 4 (0 to 22) | 21 (10 to 35) |
PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.
| days | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|
| Phase 2: Progression-free Survival (PFS) | 164 (78 to 239) | 49 (41 to 78) | 72 (43 to 96) | 92 (72 to 120) | 49 (42 to 96) |
Time in days from start of study treatment to first documentation of objective tumor progression. Tumor progression as per RECIST 1.1 was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1or more new lesions is also considered progression.
| days | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|
| Phase 2: Time to Disease Progression (TTP) | 164 (78 to 239) | 46 (40 to 86) | 72 (43 to 96) | 92 (74 to 144) | 78 (42 to 114) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response=(the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1). CR: complete disappearance of all target lesions and non-target disease, except nodal disease; all nodes decreased to normal; no new lesions. PR: \>=30% decrease under baseline of the sum of diameters of all target lesions; no unequivocal progression of non-target disease; no new lesions. Tumor progression: \>=20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study); absolute increase of \>=5 mm; appearance of \>=1 new lesions is also considered progression. DOR calculated for the subgroup of participants with objective response.
| days | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|
| Phase 2: Duration of Response (DOR) | 169 (85 to 313) | 198 (146 to 501) | 79 (46 to 95) | NA (NA to NA) | 125 (93 to 365) |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.
| participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|
| Adverse Events | 52 | 52 | 54 | 26 | 57 |
| Serious Adverse Events | 23 | 30 | 19 | 8 | 28 |
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| nanomole (nM) | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg (Including Pancreatic Cancer) | Phase 1: MLN8237 60 mg |
|---|---|---|---|---|---|
| Day 1 (n = 1, 3, 4, 13, 3) | 297 | 602 ± 15 | 949 ± 49 | 1619 ± 39 | 1696 ± 37 |
| Day 7 (n = 1, 3, 3, 12, 2) | 981 | 1279 ± 35 | 1830 ± 39 | 2907 ± 49 | 3027 ± NA |
Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.
| hours | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg (Including Pancreatic Cancer) | Phase 1: MLN8237 60 mg |
|---|---|---|---|---|---|
| Day 1 (n = 1, 3, 4, 13, 3) | 2.9 | 2.0 (2 to 2.9) | 3.2 (2.8 to 6) | 2.2 (1.7 to 11) | 6.0 (3 to 7.9) |
| Day 7 (n = 1, 3, 3, 12, 2) | 3.1 | 3.0 (1 to 6) | 3.0 (2 to 6) | 2.4 (0 to 8) | 2.8 (2.6 to 3.0) |
Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.
| nanomole*hour (nM*hr) | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg (Including Pancreatic Cancer) | Phase 1: MLN8237 60 mg |
|---|---|---|---|---|---|
| Day 1 (n = 1, 3, 4, 13, 3) | 2640 | 3495 ± 19 | 5015 ± 57 | 10736 ± 48 | 13932 ± 42 |
| Day 7 (n = 1, 3, 3, 11, 2) | 8660 | 10184 ± 24 | 13694 ± 59 | 20867 ± 49 | 28709 ± NA |
Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
| hours | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg (Including Pancreatic Cancer) | Phase 1: MLN8237 60 mg |
|---|---|---|---|---|---|
| Phase 1: Terminal Phase Elimination Half-life (T1/2) for Alisertib | 20.6 | 16.0 ± 1.2 | 19.0 ± NA | 20.8 ± 10.3 | 27.8 ± NA |
Rac was estimated as a ratio of AUC (0-tau) at Day 7 and AUC (0-tau) at Day 1. Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.
| ratio | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg (Including Pancreatic Cancer) | Phase 1: MLN8237 60 mg |
|---|---|---|---|---|---|
| Phase 1: Rac- Accumulation Ratio for Alisertib | 3.3 | 3.0 ± 1.0 | 2.3 ± 0.4 | 2.2 ± 0.9 | 2.4 ± NA |
Peak to trough ratio was estimated as a ratio of Cmax at Day 7 and the minimum observed plasma concentration (Ctrough) of alisertib at Day 7. Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Ctrough is the minimum plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ratio | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg (Including Pancreatic Cancer) | Phase 1: MLN8237 60 mg |
|---|---|---|---|---|---|
| Phase 1: Peak to Trough Ratio for Alisertib | 1.7 | 2.1 ± 0.7 | 2.3 ± 1.4 | 2.3 ± 0.8 | 1.8 ± NA |
CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-tau), expressed in liter per hour (L/hr).
| L/hr | Phase 1: MLN8237 10 mg | Phase 1: MLN8237 20 mg | Phase 1: MLN8237 40 mg | Phase 1: MLN8237 50 mg (Including Pancreatic Cancer) | Phase 1: MLN8237 60 mg |
|---|---|---|---|---|---|
| Phase 1: Steady State Oral Clearance (CLss/F) for Alisertib | 2.2 | 3.8 ± 22 | 5.6 ± 72 | 4.6 ± 39 | 4.0 ± NA |
In SCLC,chemo-sensitive/resistant population were analyzed;in breast cancers,ER2 and ER2 status were analyzed.HR+ =estrogen receptor-positive or progesterone receptor-positive. HER+ =human epidermal growth factor receptor 2 (HER2). Triple negative =negative for estrogen receptors, progesterone receptors, and HER2.Clinical response according to RECIST version 1.1. CR:complete disappearance of all target lesions,non-target disease,except nodal disease;all nodes decrease to normal (short axis \<10 mm);no new lesions. PR:\>=30% decrease under baseline of the sum of diameters of all target lesions (SLD);short axis was used in the sum for target nodes,longest diameter used in the sum for all other target lesions;no unequivocal progression of non-target disease;no new lesions. Progressive Disease (PD): \>=20% rise in SLD from the smallest value on study;unequivocal progression of existing non-target lesions. Stable Disease (SD):Neither sufficient shrinkage for PR nor sufficient increase for PD.
| percentage of participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|
| HR+: CR (n=26, 0, 0, 0, 0) | 0 (NA to NA) | — | — | — | NA (NA to NA) |
| HR+: PR (n=26, 0, 0, 0, 0) | 23 (9 to 44) | — | — | — | NA (NA to NA) |
| HR+: SD (n=26, 0, 0, 0, 0) | 65 (44 to 83) | — | — | — | NA (NA to NA) |
| HR+: PD (n=26, 0, 0, 0, 0) | 12 (2 to 30) | — | — | — | NA (NA to NA) |
| HER+: CR (n=9, 0, 0, 0, 0) | 0 (NA to NA) | — | — | — | NA (NA to NA) |
| HER+: PR (n=9, 0, 0, 0, 0) | 22 (3 to 60) | — | — | — | NA (NA to NA) |
| HER+: SD (n=9, 0, 0, 0, 0) | 36 (13 to 65) | — | — | — | NA (NA to NA) |
| HER+: PD (n=9, 0, 0, 0, 0) | 44 (14 to 79) | — | — | — | NA (NA to NA) |
| Triple Negative: CR (n=14, 0, 0, 0, 0) | 0 (NA to NA) | — | — | — | NA (NA to NA) |
| Triple Negative: PR (n=14, 0, 0, 0, 0) | 7 (0 to 34) | — | — | — | NA (NA to NA) |
| Triple Negative: SD (n=14, 0, 0, 0, 0) | 36 (13 to 65) | — | — | — | NA (NA to NA) |
| Triple Negative: PD (n=14, 0, 0, 0, 0) | 57 (29 to 82) | — | — | — | NA (NA to NA) |
| Chemotherapy Refractory:CR(n=0,0,0,0,12) | NA (NA to NA) | — | — | — | 0 (NA to NA) |
| Chemotherapy Refractory:PR(n=0,0,0,0,12) | NA (NA to NA) | — | — | — | 25 (5 to 57) |
| Chemotherapy Refractory:SD(n=0,0,0,0,12) | NA (NA to NA) | — | — | — | 25 (5 to 57) |
| Chemotherapy Refractory:PD(n=0,0,0,0,12) | NA (NA to NA) | — | — | — | 50 (21 to 79) |
| Chemotherapy Sensitive: CR(n=0,0,0,0,36) | NA (NA to NA) | — | — | — | 0 (NA to NA) |
| Chemotherapy Sensitive: PR(n=0,0,0,0,36) | NA (NA to NA) | — | — | — | 19 (8 to 36) |
| Chemotherapy Sensitive: SD(n=0,0,0,0,36) | NA (NA to NA) | — | — | — | 36 (21 to 54) |
| Chemotherapy Sensitive: PD(n=0,0,0,0,36) | NA (NA to NA) | — | — | — | 44 (28 to 62) |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: MLN8237- Dose Escalation | — | 13/23 (56.5%) | 23/23 (100%) |
| Phase 1: MLN8237 50 mg- Pancreatic Cancer | — | 1/1 (100%) | 1/1 (100%) |
| Phase 2: MLN8237 50 mg- Breast Cancer | — | 23/53 (43.4%) | 52/53 (98.1%) |
| Phase 2: MLN8237 50 mg- Gastric Cancer | — | 30/55 (54.5%) | 52/55 (94.5%) |
| Phase 2: MLN8237 50 mg- HNSCC | — | 19/55 (34.5%) | 54/55 (98.2%) |
| Phase 2: MLN8237 50 mg- NSCLC | — | 8/26 (30.8%) | 26/26 (100%) |
| Phase 2: MLN8237 50 mg- SCLC | — | 28/60 (46.7%) | 55/60 (91.7%) |
| Event | Phase 1: MLN8237- Dose Escalation | Phase 1: MLN8237 50 mg- Pancreatic Cancer | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/23 | 1/1 | 2/53 | 2/55 | 1/55 | 0/26 | 2/60 |
| NauseaGastrointestinal disorders | 2/23 | 1/1 | 2/53 | 0/55 | 0/55 | 0/26 | 0/60 |
| LeukopeniaBlood and lymphatic system disorders | 1/23 | 1/1 | 1/53 | 1/55 | 0/55 | 0/26 | 0/60 |
| StomatitisGastrointestinal disorders | 0/23 | 1/1 | 0/53 | 1/55 | 1/55 | 0/26 | 1/60 |
| Flank painMusculoskeletal and connective tissue disorders | 0/23 | 1/1 | 0/53 | 0/55 | 0/55 | 0/26 | 0/60 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/23 | 1/1 | 0/53 | 0/55 | 0/55 | 0/26 | 0/60 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/23 | 0/1 | 2/53 | 2/55 | 2/55 | 0/26 | 4/60 |
| VomitingGastrointestinal disorders | 3/23 | 0/1 | 1/53 | 1/55 | 0/55 | 0/26 | 1/60 |
| AnaemiaBlood and lymphatic system disorders | 2/23 | 0/1 | 2/53 | 4/55 | 1/55 | 3/26 | 5/60 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/23 | 0/1 | 0/53 | 2/55 | 0/55 | 0/26 | 0/60 |
| Event | Phase 1: MLN8237- Dose Escalation | Phase 1: MLN8237 50 mg- Pancreatic Cancer | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 13/23 | 1/1 | 29/53 | 24/55 | 26/55 | 15/26 | 27/60 |
| AnaemiaBlood and lymphatic system disorders | 4/23 | 1/1 | 20/53 | 25/55 | 24/55 | 13/26 | 16/60 |
| VomitingGastrointestinal disorders | 8/23 | 1/1 | 11/53 | 16/55 | 13/55 | 6/26 | 10/60 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/23 | 1/1 | 11/53 | 14/55 | 7/55 | 6/26 | 11/60 |
| HypokalaemiaMetabolism and nutrition disorders | 2/23 | 1/1 | 5/53 | 4/55 | 2/55 | 2/26 | 4/60 |
| NeutropeniaBlood and lymphatic system disorders | 10/23 | 0/1 | 31/53 | 23/55 | 25/55 | 15/26 | 21/60 |
| Decreased appetiteMetabolism and nutrition disorders | 13/23 | 0/1 | 13/53 | 15/55 | 12/55 | 5/26 | 18/60 |
| DiarrhoeaGastrointestinal disorders | 10/23 | 0/1 | 27/53 | 21/55 | 15/55 | 9/26 | 17/60 |
| AlopeciaSkin and subcutaneous tissue disorders | 10/23 | 0/1 | 26/53 | 21/55 | 24/55 | 11/26 | 16/60 |
| NauseaGastrointestinal disorders | 11/23 | 0/1 | 15/53 | 18/55 | 14/55 | 12/26 | 18/60 |
| Age, Customized(participants) | Phase 1: MLN8237- All Participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC | Total |
|---|---|---|---|---|---|---|---|
| 18-64 years | 17 | 37 | 33 | 38 | 17 | 38 | 180 |
| 65-84 years | 7 | 16 | 21 | 17 | 9 | 22 | 92 |
| 85 years and over | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Phase 1: MLN8237- All Participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC | Total |
|---|---|---|---|---|---|---|---|
| Female | 9 | 53 | 12 | 3 | 12 | 28 | 117 |
| Male | 15 | 0 | 43 | 52 | 14 | 32 | 156 |
| Race/Ethnicity, Customized(participants) | Phase 1: MLN8237- All Participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 2 | 1 | 1 | 1 | 12 |
| Not Hispanic or Latino | 19 | 48 | 49 | 50 | 25 | 57 | 248 |
| Not reported | 2 | 1 | 4 | 4 | 0 | 2 | 13 |
| Race/Ethnicity, Customized(participants) | Phase 1: MLN8237- All Participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC | Total |
|---|---|---|---|---|---|---|---|
| White | 18 | 49 | 51 | 53 | 22 | 56 | 249 |
| Black or African American | 3 | 1 | 3 | 2 | 2 | 4 | 15 |
| Asian | 2 | 1 | 0 | 0 | 1 | 0 | 4 |
| Chinese | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Other | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Not reported | 1 | 1 | 1 | 0 | 0 | 0 | 3 |
| Region of Enrollment(participants) | Phase 1: MLN8237- All Participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC | Total |
|---|---|---|---|---|---|---|---|
| Czech Republic | 0 | 19 | 20 | 8 | 7 | 15 | 69 |
| France | 0 | 10 | 8 | 11 | 3 | 8 | 40 |
| Poland | 0 | 1 | 0 | 1 | 0 | 7 | 9 |
| United States | 24 | 23 | 27 | 35 | 16 | 30 | 155 |
| Disease stage at study entry(participants) | Phase 1: MLN8237- All Participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC | Total |
|---|---|---|---|---|---|---|---|
| IA | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| II | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| III | 1 | 0 | 1 | 2 | 0 | 0 | 4 |
| IIIA | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| IIIB | 0 | 3 | 0 | 0 | 5 | 2 | 10 |
| IIIC | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| IV | 19 | 48 | 54 | 2 | 21 | 57 | 201 |
| IVA | 1 | 0 | 0 | 23 | 0 | 0 | 24 |
| IVB | 1 | 0 | 0 | 2 | 0 | 0 | 3 |
| IVC | 0 | 0 | 0 | 25 | 0 | 0 | 25 |
| Eastern Cooperative Oncology Group (ECOG) performance status(participants) | Phase 1: MLN8237- All Participants | Phase 2: MLN8237 50 mg- Breast Cancer | Phase 2: MLN8237 50 mg- Gastric Cancer | Phase 2: MLN8237 50 mg- HNSCC | Phase 2: MLN8237 50 mg- NSCLC | Phase 2: MLN8237 50 mg- SCLC | Total |
|---|---|---|---|---|---|---|---|
| 0 | 4 | 23 | 21 | 17 | 7 | 13 | 85 |
| 1 | 20 | 30 | 34 | 38 | 19 | 47 | 188 |
The record gives a start of Feb 2010, a primary completion of May 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Carcinoma, Non-Small-Cell Lung →
Millennium Pharmaceuticals, Inc. →